PropertyValue
nif:beginIndex
  • 0 (xsd:integer)
nif:broaderContext
nif:endIndex
  • 204 (xsd:integer)
nif:isString
  • However, we found significantly higher OR for surrogate endpoints in for-profit-funded drug trials (OR 4.10, 95% CI 2.64-6.37) than in nonprofit-funded drug trials (OR 1.66, 95% CI 1.11-2.47) (Table [5]).
rdf:type